The Association for Frontotemporal Degeneration and the Alzheimer's Drug Discovery Foundation have announced gifts totaling $10 million in support of efforts to develop effective treatments for frontotemporal degeneration (FTD).
The gifts of $5 million from Leonard A. and Ronald S. Lauder and the Lauder Foundation and $5 million from the Samuel I. Newhouse Foundation will establish the Treat FTD Fund, a joint program of AFTD and ADDF that will work to advance clinical trials for FTD, a complex form of dementia that affects more than fifty thousand people in the United States. The fund — which will support clinical trials for new as well as "repurposed" drugs — drugs approved for one disease that are then tested for use in others — will build on recent AFTD and ADDF successes in early-stage drug discovery and biomarker development. Through the fund, the two organizations also will work to involve additional funders in drug research for FTD and other diseases of the brain.
"My brother and co-chairman, Ronald S. Lauder, and I founded ADDF to find treatments for Alzheimer's and other causes of dementia," said Leonard A. Lauder, president of the Lauder Foundation and ADDF co-chair. "Partnerships have always been an important part of that mission because they allow us to combine resources and to develop effective drugs faster."